INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is a common malignant tumor of digestive system, and a complex disease caused by interactions between multiple genetic and environmental factors \[[@R1], [@R2]\]. There are about 800,000 new cases of HCC around the world each year, of which more than 50% occurs in China \[[@R3], [@R4]\]. Guangxi is one region with the highest incidence of HCC in China, where HCC is the leading cause of tumor-related mortality. Because of insidious onset and high malignancy, most HCC patients are diagnosed in advanced stage with poor prognosis. Although comprehensive treatment based on surgery has improved the curative effect of HCC greatly, clinical cure rate and long-term survival rate have no significant improvement. Recently, studies on the causes, prognosis markers, molecular targets and carcinogenesis mechanisms of HCC are increasing widely \[[@R5]--[@R8]\], but the exact molecular mechanism is still not well understood. Therefore, it is very crucial to find the molecular markers which can be used in the risk and prognosis evaluation for the prevention and treatment of HCC.

Single nucleotide polymorphism (SNP) is the third generation of molecular marker and one of the most common genetic variations in human. Studies show that SNP can not only be used as a genetic marker locating disease gene, some SNP itself can also directly lead to the occurrence of diseases \[[@R9], [@R10]\]. Thus SNP has crucial function and application in disease risk assessment, early diagnosis, prevention, treatment and drug development \[[@R11]--[@R13]\]. Mismatch repair (MMR) system is a DNA repair system with a high fidelity. It mainly repairs base mismatch and insertion/deletion ring produced in the synthesis of DNA to maintain the stability of the whole genome \[[@R14]--[@R16]\]. MutL homolog 1 (MLH1) plays a key role in the MMR system. MLH1 recognizes and repairs the mismatched bases in the process of DNA replication, and also recruits other mismatch repair proteins to the mismatch site to correct DNA replication error \[[@R17], [@R18]\]. Studies found that SNPs of specific DNA repair genes could affect the expression level and activity of enzymes and individual DNA damage repair efficiency. Repair gene defects may lead to genetic instability and cancer occurrence, suggesting that individual differences in cancer risk was related to polymorphisms of specific repair genes \[[@R19]--[@R21]\]. It has been reported *MLH1* polymorphisms had a correlation with the pathogenesis of colorectal cancer, lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, oral squamous cell carcinoma \[[@R19]--[@R27]\]. However, there is only a few researches about the relationship between *MLH1* polymorphism and HCC \[[@R28]\], and the results still need further verification due to race, nation, region and individual differences.

In order to clarify genetic variations of *MLH1* in HCC, this study aims to screen potential *MLH1* SNPs in a case-control study from a HCC population in Guangxi. Four *MLH1* SNPs, rs1800734, rs10849, rs3774343 and rs1540354, that minor allele frequency (MAF) was more than 0.05, were selected from the National Institute of Environmental Health Sciences (NIEHS) database. Through the investigation and collection of demographic and clinical information from the study population, the relationships between these *MLH1* SNPs with risk and prognosis of HCC were analyzed. Finally, we found that rs1800734 was a new predictor for poor prognosis of HCC patients.

RESULTS {#s2}
=======

General demographic characteristics of study population and Hardy-Weinberg equilibrium test results {#s2_1}
---------------------------------------------------------------------------------------------------

The general demographic characteristics of study population were shown in Table [1](#T1){ref-type="table"}. The case and control group were significantly different at alcohol intake, smoking, HBV infection and family history (*P* \< 0.001). However, there was no difference about gender, age or nation between the two groups (*P* \> 0.05).

###### Distributions of general demographic characteristics and environmental risk factors in the controls and cases

  Characteristics   Controls (*n* = 1036)   Cases (*n* = 1036)   χ^2^      *P*
  ----------------- ----------------------- -------------------- --------- --------------
  Age (years)                                                              
   \< 50            497                     532                  2.365     0.124
   ≥ 50             539                     504                            
  Gender                                                                   
   Male             896                     896                  0.000     1.000
   Female           140                     140                            
  Nation                                                                   
   Han              736                     715                  1.048     0.592
   Zhuang           286                     305                            
   Others           14                      16                             
  Smoking                                                                  
   No               879                     674                  108.03    **\< 0.001**
   Yes              157                     362                            
  Alcohol intake                                                           
   No               895                     689                  113.75    **\< 0.001**
   Yes              141                     347                            
  HBV infection                                                            
   No               953                     176                  1174.97   **\< 0.001**
   Yes              83                      860                            
  Family history                                                           
   No               1022                    975                  30.56     **\< 0.001**
   Yes              14                      61                             

Bold values indicate significance.

Haploview 4.2 test showed genotype distribution of the four *MLH1* SNPs, rs1800734, rs10849, rs3774343, and rs1540354 accorded with the HWE equilibrium in the control group ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

The relationship between genotype distribution of *MLH1* SNPs and HCC risk {#s2_2}
--------------------------------------------------------------------------

Multivariate logistic regression analysis showed that *MLH1* SNP, rs1800734 had a significant difference between the case and control group (Table [2](#T2){ref-type="table"}, *P* \< 0.05). After adjusted for age, gender, smoking, alcohol intake and HBV infection, compared with the AA genotype, the ORs (95% CI) of AG, GG and AG/GG genotype with HCC risk were 1.217 (1.074∼1.536), 1.745 (1.301∼2.591) and 1.291 (1.126∼1.687), respectively. The other three *MLH1* SNPs, rs10849, rs3774343 and rs1540354 had no statistically significant differences between the case and control group (*P* \> 0.05).

###### The genotype frequencies of MLH1 polymorphisms and HCC risk

  ----------------------------------------------------------------------------------------------------------------------
  Genotypes       Cases (%)      Controls (%)   Frequencies in\      OR (95% CI)^a^            OR (95% CI)^b^
                                                HapMap project (%)                             
  --------------- -------------- -------------- -------------------- ------------------------- -------------------------
  **rs1800734**                                                                                

  AA              393 (37.16)    338 (32.63)    30.23                1.000                     1.000

  AG              522 (50.39)    529 (51.06)    44.19                1.178 (0.975∼1.424)       **1.217 (1.074∼1.536)**

  GG              121 (12.45)    169 (16.31)    25.58                **1.624 (1.234∼2.138)**   **1.745 (1.301∼2.591)**

  AG/GG           643 (62.84)    675 (67.37)    69.77                **1.221 (1.018∼1.463)**   **1.291 (1.126∼1.687)**

  A               1308 (63.13)   1205 (58.16)   52.33                \-                        \-

  G               764 (36.87)    867 (41.84)    47.67                \-                        \-

  **rs10849**                                                                                  

  AA              7 (0.67)       3 (0.29)       0                    1.000                     1.000

  AG              151 (14.58)    162 (15.64)    0.19                 2.503 (0.636∼9.857)       2.625 (0.651∼11.236)

  GG              878 (84.75)    871 (84.07)    0.81                 2.315 (0.597∼8.890)       2.431 (0.605∼9.873)

  AG/GG           1029 (99.33)   1033 (99.71)   100.00               2.342 (0.604∼9.083)       2.526 (0.612∼10.585)

  A               165 (7.96)     168 (8.11)     9.30                 \-                        \-

  G               1907 (92.04)   1904 (91.89)   90.70                \-                        \-

  **rs3774343**                                                                                

  CC              8 (0.77)       2 (0.19)       0                    1.000                     1.000

  CT              143 (13.80)    125 (12.06)    11.63                3.497 (0.729∼16.772)      3.624 (0.756∼19.245)

  TT              885 (85.43)    909 (87.75)    88.37                4.108 (0.870∼19.401)      4.162 (0.923∼21.523)

  CT/TT           1028 (90.23)   1034 (99.81)   100.00               4.023 (0.852∼18.992)      4.101 (0.891∼20.317)

  C               159 (7.67)     129 (6.23)     5.81                 \-                        \-

  T               1913 (92.33)   1943 (93.77)   94.19                \-                        \-

  **rs1540354**                                                                                

  AA              96 (9.27)      81 (7.82)      13.95                1.000                     1.000

  AT              489 (47.20)    447 (43.15)    39.53                1.083 (0.785∼1.495)       1.125 (0.813∼1.542)

  TT              451 (43.53)    508 (49.03)    46.51                1.335 (0.968∼1.842)       1.363 (0.971∼1.876)

  AT/TT           940 (90.73)    955 (92.18)    86.04                1.204 (0.884∼1.640)       1.237 (0.896∼1.679)

  A               681 (32.87)    609 (29.39)    33.72                \-                        \-

  T               1391 (67.13)   1463 (70.61)   66.28                \-                        \-
  ----------------------------------------------------------------------------------------------------------------------

a: OR (95% CI) not adjusted; b: OR (95% CI) adjusted by logistic regression for age, gender, nation, smoking, alcohol intake, HBV infection, and HCC family history. Bold values indicate significance.

Gene-environment and SNP-SNP interaction {#s2_3}
----------------------------------------

Logistic regression model analysis showed that rs1800734, rs10849 and rs3774343 had interactions with such environment factors, HBV infection, alcohol intake and smoking in the pathogenesis of HCC (Table [3](#T3){ref-type="table"}, *P* \< 0.05).

###### Gene-environment interaction

  Factors                      *β*     *S.E.*   *Wald χ*^*2*^   OR (95% CI)^a^        *P*
  ---------------------------- ------- -------- --------------- --------------------- -----------
  rs1800734 × Smoking          0.263   0.116    6.354           1.195(1.040∼2.270)    **0.012**
  rs1800734 × Alcohol intake   0.358   0.103    14.660          1.294(1.134∼2.132)    **0.000**
  rs1800734 × HBV infection    2.132   0.127    735.759         8.685(6.136∼13.246)   **0.000**
  rs1800734 × Family history   0.210   0.235    1.862           1.105(0.748∼1.982)    0.176
  rs10849 × Smoking            0.253   0.109    6.102           1.183(1.036∼2.131)    **0.014**
  rs10849 × Alcohol intake     0.342   0.121    11.638          1.217(1.097∼2.061)    **0.000**
  rs10849 × HBV infection      1.532   0.127    657.842         5.685(4.136∼9.246)    **0.000**
  rs10849 × Family history     0.198   0.213    1.721           1.079(0.676∼1.837)    0.225
  rs3774343 × Smoking          0.232   0.123    5.657           1.152(1.027∼1.846)    **0.021**
  rs3774343 × Alcohol intake   0.326   0.113    9.597           1.198(1.071∼1.956)    **0.007**
  rs3774343 × HBV infection    1.392   0.115    548.985         4.913(3.694∼8.635)    **0.000**
  rs3774343 × Family history   0.191   0.261    1.678           1.024(0.651∼1.736)    0.292
  rs1540354 × Smoking          0.245   0.129    6.047           1.197(1.065∼1.976)    **0.019**
  rs1540354 × Alcohol intake   0.317   0.124    10.436          1.209(1.087∼2.012)    **0.011**
  rs1540354 × HBV infection    1.516   0.117    632.761         5.215(3.956∼8.957)    **0.000**
  rs1540354 × Family history   0.211   0.221    1.702           1.105(0.672∼1.894)    0.258

^a^: OR (95% CI) adjusted by logistic regression for age, gender, nations, smoking, alcohol intake, HBV infection, and HCC family history. Bold values indicate significance.

In addition, as shown in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}, rs1800734 and rs10849, rs1800734 and rs3774343, rs1800734 and rs1540354 had SNP-SNP interactions in the pathogenesis of HCC (*P* \< 0.05), and these interactions could increase HCC risk.

Associations between *MLH1* polymorphisms with clinical-pathological characteristics and the prognosis of HCC patients {#s2_4}
----------------------------------------------------------------------------------------------------------------------

As shown in Table [4](#T4){ref-type="table"}, *MLH1* SNP, rs1800734 was correlated with tumor size, staging and AFP level of HCC patients (*P* \< 0.05), while rs10849, rs3774343 and rs1540354 had no association with these clinical-pathological characteristics of HCC patients.

###### The associations between the MLH1 polymorphisms and clinical characteristics of HCC patients

  Variables              AA            AG/GG         OR (95% CI)^a^         OR (95% CI)^b^
  ---------------------- ------------- ------------- ---------------------- ----------------------
  **rs1800734**                                                             
  Tumor size                                                                
  \< 5 cm                311 (29.17)   455 (70.83)   1.000                  1.000
  ≥ 5 cm                 82 (34.56)    188 (63.44)   1.567 (1.165∼2.109)    1.671 (1.215∼2.252)
  Tumor number                                                              
  solitary               332 (30.58)   514 (69.42)   1.000                  1.000
  multiple               61 (29.91)    129 (70.09)   1.366 (0.978∼1.908)    1.379 (0.988∼1.926)
  TNM staging                                                               
  T1 + T2                337 (31.30)   518 (68.70)   1.000                  1.000
  T3 + T4                56 (26.14)    125 (74.86)   1.452 (1.030∼2.048)    1.545 (1.092∼2.185)
  AFP level (ng/ml)                                                         
  \< 400                 152 (37.16)   206 (62.84)   1.000                  1.000
  ≥ 400                  241 (29.45)   437 (70.55)   1.338 (1.030∼1.739)    1.463 (1.126∼1.903)
  Lymphatic metastasis                                                      
  No                     343 (29.02)   535 (70.98)   1.000                  1.000
  Yes                    50 (40.15)    107 (59.85)   1.372 (0.955∼1.971)    1.433 (0.996∼2.061)
  **rs10849**                                                               
  Tumor size                                                                
  \< 5 cm                5 (4.64)      761 (95.36)   1.000                  1.000
  ≥ 5 cm                 2 (7.32)      268 (92.68)   0.880 (0.170∼4.565)    0.913 (0.215∼5.294)
  Tumor number                                                              
  solitary               6 (5.50)      840 (94.50)   1.000                  1.000
  multiple               1 (2.56)      189 (97.44)   1.350 (0.162∼11.279)   1.401 (0.168∼11.706)
  TNM staging                                                               
  T1+T2                  6 (5.73)      849 (94.27)   1.000                  1.000
  T3+T4                  1 (1.96)      180 (98.04)   1.272 (0.152∼10.631)   1.315 (0.163∼11.129)
  AFP level (ng/ml)                                                         
  \< 400                 3 (6.89)      355 (93.10)   1.000                  1.000
  ≥ 400                  4 (4.74)      674 (95.26)   1.424 (0.317∼6.397)    1.87 (0.331∼6.681)
  Lymphatic metastasis                                                      
  No                     7 (5.24)      871 (94.76)   1.000                  1.000
  Yes                    0 (38.22)     157 (61.78)   0.000                  0.000

  **Variables**          **CC**     **CT/TT**     **OR (95% CI)^a^**     **OR (95% CI)^b^**
  ---------------------- ---------- ------------- ---------------------- ----------------------
  **rs3774343**                                                          
  Tumor size                                                             
  \< 5 cm                6 (3.23)   760 (96.77)   1.000                  1.000
  ≥ 5 cm                 2 (2.44)   268 (97.56)   1.058 (0.212∼5.273)    1.117 (0.224∼5.569)
  Tumor number                                                           
  solitary               7 (3.09)   839 (96.91)   1.000                  1.000
  multiple               1 (2.56)   189 (97.44)   1.577 (0.193∼12.893)   1.635 (0.206∼13.614)
  TNM staging                                                            
  T1 + T2                7 (3.58)   848 (96.42)   1.000                  1.000
  T3 + T4                1 (3.92)   180 (96.08)   1.486 (0.182∼12.151)   1.537 (0.196∼13.513)
  AFP level (ng/ml)                                                      
  \< 400                 3 (1.02)   355 (98.98)   1.000                  1.000
  ≥ 400                  5 (3.88)   673 (96.12)   1.137 (0.270∼4.787)    1.198 (0.305∼5.477)
  Lymphatic metastasis                                                   
  No                     8 (3.50)   870 (96.50)   1.000                  1.000
  Yes                    0 (4.55)   157 (95.45)   0.000                  0.000

  **Variables**          **AA**       **AT/TT**     **OR (95% CI)^a^**    **OR (95% CI)^b^**
  ---------------------- ------------ ------------- --------------------- ---------------------
  **rs1540354**                                                           
  Tumor size                                                              
  \< 5 cm                75 (67.34)   691 (32.66)   1.000                 1.000
  ≥ 5 cm                 21 (67.07)   249 (32.93)   1.287 (0.777∼2.133)   1.369 (0.819∼2.288)
  Tumor number                                                            
  solitary               81 (69.76)   765 (30.24)   1.000                 1.000
  multiple               15 (66.66)   175 (33.34)   1.235 (0.695∼2.195)   1.324 (0.733∼2.389)
  TNM staging                                                             
  T1 + T2                77 (70.25)   778 (29.75)   1.000                 1.000
  T3 + T4                19 (64.00)   162 (36.00)   0.844 (0.497∼1.433)   0.875 (0.518∼1.532)
  AFP level (ng/ml)                                                       
  \< 400                 36 (69.39)   322 (30.61)   1.000                 1.000
  ≥ 400                  60 (69.40)   618 (30.60)   1.152 (0.746∼1.778)   1.216 (0.792∼1.865)
  Lymphatic metastasis                                                    
  No                     86 (68.31)   792 (31.69)   1.000                 1.000
  Yes                    10 (75.00)   148 (25.00)   1.607 (0.816∼3.166)   1.786 (0.879∼3.627)

^a^: OR (95% CI) not adjusted; ^b^: OR (95% CI) adjusted by logistic regression for age, gender, nation, smoking, alcohol intake, HBV infection, and HCC family history.

At the end of the follow-up, there were 37.84% (165/436) of HCC patients died. We found that the prognosis of HCC had a correlation with these clinical-pathological characteristics of patients, such as tumor size, number, staging, AFP level and lymph node metastasis (*P* \< 0.05, Table [5](#T5){ref-type="table"}), but was not associated with age, gender, HBV infection or family history (*P* \> 0.05).

###### The associations between general demographic and clinical characteristics with the prognosis of HCC patients

  Variables              Cases   Survivors   MST    Log-rank *P*           HR (95% CI)
  ---------------------- ------- ----------- ------ ---------------------- -------------
  Age (years)                                                              
   \< 50                 268     172         49.0   0.650                  1.000
   ≥ 50                  168     99          46.7   1.074 (0.788--1.464)   
  Gender                                                                   
   Male                  353     222         48.7   0.723                  1.000
   Female                83      49          46.4   0.934 (0.639--1.365)   
  HBV infection                                                            
   No                    62      38          46.4   0.951                  1.000
   Yes                   374     233         48.7   0.821 (0.617--1.467)   
  Family history                                                           
   No                    399     248         48.6   0.917                  1.000
   Yes                   37      23          46.7   0.971 (0.561--1.681)   
  Tumor size                                                               
   \< 5 cm               243     171         51.5   **0.001**              1.000
   ≥ 5 cm                193     100         44.9   1.668 (1.226--2.270)   
  Tumor number                                                             
   solitary              288     202         51.5   **0.000**              1.000
   multiple              148     69          43.5   1.746 (1.300--2.395)   
  TNM staging                                                              
   T1 + T2               300     214         56.0   **0.000**              1.000
   T3 + T4               136     57          38.4   1.471 (1.053--2.054)   
  AFP level (ng/ml)                                                        
   \< 400                169     120         51.0   **0.023**              1.000
   ≥ 400                 267     151         45.3   1.520 (1.080--2.138)   
  Lymphatic metastasis                                                     
   No                    381     254         49.6   **0.000**              1.000
   Yes                   55      17          32.3   2.458 (1.710--3.533)   

Bold values indicate significance.

Moreover, the co-dominant and dominant models of rs1800734 had a significant influence on the prognosis of HCC (Table [6](#T6){ref-type="table"}, Figure [1](#F1){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Compared with the AA genotype, the survival time of HCC patients with AG, GG and AG/GG genotype significantly decreased (*P* \< 0.05). But the recessive model of rs1800734 had no effect on the survival time of HCC patients. The genotypes of the other three *MLH1* SNPs, rs10849, rs3774343 and rs1540354 had no effect on the survival time of HCC patients (Figure [1](#F1){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

###### The associations between MLH1 polymorphisms and the prognosis of HCC patients

  SNPs            Genotypes   Survivors / Cases   MST (Months)   Log-rank *P*   HR (95% CI)
  --------------- ----------- ------------------- -------------- -------------- ----------------------
  **rs1800734**                                                                 
  Co-dominant     AA          110/163             56.0           **0.000**      1.553 (1.257--1.920)
                  AG          126/212             42.0                          
                  GG          35/61               45.1                          
  Dominant        AA          110/163             56.0           **0.000**      2.207 (1.572--3.100)
                  AG/GG       161/273             44.3                          
  Recessive       AG/AA       236/375             48.7           0.120          1.393 (0.915--2.122)
                  GG          35/61               45.1                          
  **rs10849**                                                                   
  Co-dominant     AA          1/4                 22.6           0.548          0.908 (0.631--1.307)
                  AG          47/72               48.6                          
                  GG          223/360             47.6                          
  Dominant        AA          1/4                 22.6           0.273          0.530 (0.166--1.685)
                  AG/GG       270/432             48.6                          
                                                                                
  Recessive       AG/AA       48/76               48.6           0.780          0.944 (0.628--1.418)
                  GG          223/360             47.6                          
  **rs3774343**                                                                 
  Co-dominant     CC          2/5                 23.8           0.371          1.091 (0.756--1.573)
                  CT          55/81               46.7                          
                  TT          214/350             48.6                          
                                                                                
  Dominant        CC          2/5                 23.8           0.316          0.559 (0.176--1.776)
                  CT/TT       269/431             48.6                          
                                                                                
  Recessive       CT/CC       57/86               46.7           0.450          1.167 (0.781--1.744)
                  TT          214/350             48.6                          
  **rs1540354**                                                                 
  Co-dominant     AA          21/39               41.3           0.435          0.903 (0.711--1.148)
                  AT          133/208             51.2                          
                  TT          117/189             48.6                          
  Dominant        AA          21/39               41.3           0.197          0.726 (0.445--1.184)
                  AT/TT       250/397             48.7                          
  Recessive       AT/AA       154/247             47.6           0.733          0.948 (0.696--1.290)
                  TT          117/189             48.6                          

Bold values indicate significance.

![The effect of *MLH1* polymorphisms on the prognosis of HCC patients\
Kaplan-Meier overall survival curves for HCC patients based on co-dominate genotypes of (**A**) rs1800734, (**B**) rs10849, (**C**) rs3774343, (**D**) rs1540354. *P* value is from the log-rank test.](oncotarget-08-80039-g001){#F1}

Regression analysis for the survival of HCC patients {#s2_5}
----------------------------------------------------

We conducted a multivariate regression analysis combined *MLH1* polymorphisms, demographic and clinical-pathological characteristics of HCC patients. As shown in Table [7](#T7){ref-type="table"}, these factors, such as rs1800734, tumor number, tumor staging and metastasis, were associated with the death risk of HCC patients.

###### COX regression analysis of the prognosis of HCC patients

  Variables      *β*     S.E.    HR      95% CI          *P*
  -------------- ------- ------- ------- --------------- -----------
  Tumor number   0.496   0.164   1.642   1.191--2.264    **0.002**
  TNM staging    0.691   0.162   1.995   1.452--2.742    **0.000**
  Metastasis     1.184   0.204   3.268   2.191--74.875   **0.000**
  rs1800734      1.289   0.194   3.629   2.481--5.310    **0.000**

Bold values indicate significance.

DISCUSSION {#s3}
==========

As the most common malignant tumor in southern Guangxi, HCC is a complex process that multiple genes and environmental factors involved \[[@R1], [@R2]\]. It is well known that environmental carcinogens cause DNA damage by continuing to attack the genomic DNA. If the damage DNA can't be repaired timely and effectively, the accumulated damage will lead to an increased genomic instability, resulting in cell apoptosis, deregulated cell proliferation and differentiation, eventually cancer \[[@R17], [@R29], [@R30]\]. Recent studies report that MLH1, a mismatch repair gene, plays an important role in carcinogenesis \[[@R19], [@R27], [@R31], [@R32]\]. SNPs of mismatch repair genes are thought to provide useful information for tumor diagnosis, suggesting that SNPs of *MLH1* may have potential value for diagnosis of HCC. However, the relationship between *MLH1* polymorphisms and HCC has not been reported in Chinese population yet.

This study analyzed the relationship between *MLH1* polymorphisms and HCC susceptibility in Guangxi area, where there is a high incidence of HCC every year. Finally, we found that the genotype distribution of rs1800734 had a significant difference between cases and controls. The AG, GG and AG/GG genotype of rs1800734 increased HCC risk compared with the AA genotype. But the other three SNPs of *MLH1*, rs10849, rs3774343 and rs1540354 were not correlated with HCC risk.

It has been reported that different populations have different genotype distribution of *MLH1* polymorphisms \[[@R15]\]. The genotype of *MLH1* polymorphisms in European and American population was mainly GG, while our results were in accordance with the genotype in Asians \[[@R24], [@R28], [@R33]\]. LO et al. explored the relationship between *MLH1* polymorphisms and lung cancer risk in a case-control study and discovered that rs1800734 was closely related to the occurrence of lung cancer \[[@R24]\]. GG genotype of rs1800734 increased the lung cancer risk compared to AA genotype. Due to genetic differences between different regions and populations, we found only rs1800734 had a correlation with the occurrence and development of HCC. The result is consistent with previous study that rs1800734 significantly increased HCC risk \[[@R28]\]. Whether the other *MLH1* polymorphisms are associated with HCC needs a prospective and large sample study to be verified.

Previous studies indicated that HBV infection, smoking, alcohol intake and family history of cancer were important environmental risk factors of HCC \[[@R6], [@R34], [@R35]\]. Thus we conducted gene-environment interaction analysis between the four *MLH1* polymorphisms and these environmental risk factors. The four *MLH1* polymorphisms were found to interact with HBV infection, alcohol intake and smoking, and increase the risk of HCC. In addition, rs1800734 had an interaction with SNPs rs10849, rs3774343 and rs1540354, these SNP-SNP interactions also increased HCC risk, suggesting that *MLH1* polymorphisms play an important role in the development of HCC. However, we didn't find any interaction between *MLH1* polymorphisms and family history of cancer, which may be due to the small sample size and low test efficiency.

HCC is a highly malignant tumor with a very poor prognosis \[[@R36]--[@R38]\]. Accumulated evidences showed that the clinical-pathological features were closely related to the prognosis of tumor, such as tumor size, tumor number, tumor stage, AFP level, lymph node metastasis, tumor thrombus, liver cirrhosis, vascular invasion and migration predicted poor prognosis for HCC \[[@R39]--[@R42]\]. This study clarified that rs1800734 was correlated with tumor size, tumor grade and AFP level, indicating that gene polymorphisms may cause carcinogenesis and different clinical-pathological features of patients \[[@R39], [@R42]\]. Furthermore, we found rs1800734, tumor number, tumor stage and lymph node metastasis were correlated with the prognosis of HCC in a COX regression analysis, and rs1800734 decreased the survival time of HCC patients significantly, suggesting that rs1800734 was a risk factor of HCC prognosis.

In addition, rs1800734 is a transcription factor binding site (TFBS), which can cause individual susceptibility difference by regulating MLH1 activity and the expression of downstream proteins \[[@R19], [@R22]\]. The relationship between rs1800734 and HCC prognosis may result from its regulation of the binding ability of transcription factors on MLH1, and then lead to expression change of MLH1 in HCC. However, the exact mechanism need further study to prove.

In summary, this is the first report of the relationship between *MLH1* polymorphisms with the risk and prognosis of HCC. We found that rs1800734 increased the risk of HCC and was a risk factor for poor prognosis of HCC, which is expected to become a new biomarker of HCC with poor prognosis.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

The study was approved by the ethics committee of the First Affiliated Hospital of Guilin Medical University. All patients were informed about the aims of sample collection and signed the informed consent in accordance with the ethical guidelines of the hospital.

Study population {#s4_2}
----------------

1,036 new cases of HCC patients were collected as the case group from Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guilin Medical University and the Guangxi Medical University between July 2009 and June 2015. These HCC patients were diagnosed as HCC by radiological or pathological methods and had not received chemotherapy and radiotherapy before the blood collection. 1,036 cases of non-HCC patients at the same time were selected as the control group from Department of Spinal Bone Marrow Surgery and Hand Trauma Surgery, the First Affiliated Hospital of Guilin Medical University and the Guangxi Medical University, with gender, age and nation matched.

Blood sample collection and investigation {#s4_3}
-----------------------------------------

The investigation questionnaire was designed after consulting experts and conducted by trained investigators in a face-to-face way. The questionnaire included general information, such as past history, personal history, family history, smoking and alcohol intake, and clinical data, such as tumor size, number, staging, portal vein tumor thrombus (PVTT), hepatitis virus infection, AFP level, histological grade, and lymph node metastasis. 2 ml peripheral blood was collected from all patients for DNA extraction. The blood DNA was stored at −80°C.

Follow up {#s4_4}
---------

475 cases of HCC patients underwent surgical resection between July 2010 and June 2015 were chosen in follow-up by telephone or outpatient review. Since the date of entering the group, they were follow-up every six months until June 2016. The survival time was counted from the first day after operation to the day when patients had metastasis, recurrence, death or the end of the follow-up. At the end of follow-up, 39 patients were lost and 436 patients had complete follow-up data.

The inclusion criteria for follow-up patients: (1) could undergo radical surgery after preoperative blood and imaging examination; (2) were confirmed as HCC by clinical pathology after radical surgery; (3) provided the blood sample; (4) had complete clinical and prognosis information; (5) signed the informed consent. The exclusion criteria for follow-up patients: (1) had not undergone radical surgery; (2) without complete clinical information; (3) refused to provide blood sample; (4) refused to sign the informed consent.

Genotyping {#s4_5}
----------

Genotyping was conducted on Applied Biosystems 7500 Fast Real-Time PCR System (ABI, United States) by TaqMan MGB high throughput RT-PCR method and the results were analyzed on 7500 Fast System V1.4.0 SDS software. For quality control, 5% sample DNA was chosen to repeat the genotyping and the concordance rate was 100%. The genotyping was repeated once again when the sample couldn't be genotyped, and the sample was abandoned if it couldn't be genotyped in the repeat genotyping.

Statistical analysis {#s4_6}
--------------------

All statistical analysis was conducted using SPSS 19.0 software. Hardy Weinberg equilibrium (HWE) test in the control group was performed using Haploview 4.2. Qualitative and quantitative data were analyzed by χ^2^ and *t* test, respectively. SNP-SNP interaction, gene-environment interaction, 95% confidence interval (CI) and odds ratio (OR) were analyzed by binary logistic regression model. The median survival time (MST) was calculated from the date of diagnosis to the date of death or the end of follow-up (June 2016). The overall survival curves were draw by Kaplan-Meier method and the differences between groups were analyzed using log-rank test. Multivariate COX regression was used for calculating hazard ratio (HR) and 95% CI. All tests were two-tailed and *P* \< 0.05 was considered statistically significant.
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